Alnylam Pharmaceuticals (LTS:0HD2) Cyclically Adjusted Book per Share: $9.22 (As of Mar. 2026)


LTS:0HD2 Alnylam Pharmaceuticals Inc LTS:0HD2
67 GF Score
Price $312.13
GF Value $517.19
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alnylam Pharmaceuticals Cyclically Adjusted Book per Share?

Alnylam Pharmaceuticals LTS:0HD2 67 Cyclically Adjusted Book per Share is $9.22 as of Mar. 2026. GuruFocus rates LTS:0HD2 with a GF Score™ of 67/100 and a GF Value™ of $517.19 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Alnylam Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $8.059. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $9.22 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Alnylam Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -12.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -9.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -3.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Alnylam Pharmaceuticals was 23.40% per year. The lowest was -9.70% per year. And the median was 10.90% per year.

As of today (2026-07-04), Alnylam Pharmaceuticals's current stock price is $312.13. Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $9.22. Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 33.85.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Alnylam Pharmaceuticals was 49.35. The lowest was 4.66. And the median was 13.24.


Alnylam Pharmaceuticals  (LTS:0HD2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=312.13/9.22
=33.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Alnylam Pharmaceuticals was 49.35. The lowest was 4.66. And the median was 13.24.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Alnylam Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Alnylam Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals Cyclically Adjusted Book per Share Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.38 12.35 12.44 11.18 9.48

Alnylam Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.46 10.15 9.73 9.48 9.22

LTS:0HD2 vs RVMD, ONC, MRNA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


LTS:0HD2
67GF Score
Alnylam Pharmaceuticals Inc LTS:0HD2
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alnylam Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alnylam Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=8.059/330.2130*330.2130
=8.059

Current CPI (Mar. 2026) = 330.2130.

Alnylam Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 12.837 241.018 17.588
201609 11.834 241.428 16.186
201612 10.708 241.432 14.646
201703 9.654 243.801 13.076
201706 12.246 244.955 16.508
201709 11.463 246.819 15.336
201712 17.723 246.524 23.740
201803 17.466 249.554 23.111
201806 16.116 251.989 21.119
201809 14.639 252.439 19.149
201812 12.868 251.233 16.913
201903 14.539 254.202 18.886
201906 15.814 256.143 20.387
201909 14.436 256.759 18.566
201912 12.824 256.974 16.479
202003 11.927 258.115 15.259
202006 12.103 257.797 15.503
202009 10.461 260.280 13.272
202012 8.729 260.474 11.066
202103 7.894 264.877 9.841
202106 7.196 271.696 8.746
202109 6.327 274.310 7.616
202112 4.894 278.802 5.796
202203 3.323 287.504 3.817
202206 1.455 296.311 1.621
202209 -0.550 296.808 -0.612
202212 -1.277 296.797 -1.421
202303 -2.087 301.836 -2.283
202306 -3.268 305.109 -3.537
202309 -1.322 307.789 -1.418
202312 -1.754 306.746 -1.888
202403 -1.734 312.332 -1.833
202406 -0.024 314.175 -0.025
202409 0.251 315.301 0.263
202412 0.519 315.605 0.543
202503 0.886 319.799 0.915
202506 1.913 322.561 1.958
202509 1.775 324.800 1.805
202512 5.962 324.054 6.075
202603 8.059 330.213 8.059

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $9.22 mean?
Alnylam Pharmaceuticals (LTS:0HD2) has a Cyclically Adjusted Book per Share of $9.22 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Alnylam Pharmaceuticals and its competitors.
Is Alnylam Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Alnylam Pharmaceuticals' current Cyclically Adjusted Book per Share is $9.22. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Cyclically Adjusted Book per Share compare to RVMD and ONC?
Alnylam Pharmaceuticals' Cyclically Adjusted Book per Share of $9.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Cyclically Adjusted Book per Share is $9.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $517.19, compared to a current price of $312.13 — trading 39.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is $9.22. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Cyclically Adjusted Book per Share is $9.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of $312.13 is trading 39.6% below its estimated GF Value™ of $517.19. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for LTS:0HD2:

  • Cyclically Adjusted Book per Share: $9.22
  • GF Value™: $517.19 vs. price of $312.13 (39.6% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score

Get the complete analysis for LTS:0HD2

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$312.13
Price
$517.19
GF Value